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Background and purpose: We compared two imaging biomarkers for dose-escalation in patients with
advanced non-small cell lung cancer (NSCLC). Treatment plans boosting metabolically active
sub-volumes deﬁned by FDG-PET or hypoxic sub-volumes deﬁned by HX4-PET were compared with
boosting the entire tumour.
Materials and methods: Ten NSCLC patients underwent FDG- and HX4-PET/CT scans prior to radiotherapy.
Three isotoxic dose-escalation plans were compared per patient: plan A, boosting the primary tumour
(PTVprim); plan B, boosting sub-volume with FDG >50% SUVmax (PTVFDG); plan C, boosting hypoxic volume
with HX4 tumour-to-background >1.4 (PTVHX4).
Results: Average boost volumes were 507 ± 466 cm3 for PTVprim, 173 ± 127 cm3 for PTVFDG and
114 ± 73 cm3 for PTVHX4. The smaller PTVHX4 overlapped on average 87 ± 16% with PTVFDG. Prescribed
dose was escalated to 87 ± 10 Gy for PTVprim, 107 ± 20 Gy for PTVFDG, and 117 ± 15 Gy for PTVHX4, with
comparable doses to the relevant organs-at-risk (OAR). Treatment plans are available online (https://
www.cancerdata.org/10.1016/j.radonc.2015.07.013).
Conclusions: Dose escalation based on metabolic sub-volumes, hypoxic sub-volumes and the entire
tumour is feasible. Highest dose was achieved for hypoxia plans, without increasing dose to OAR. For
most patients, boosting the metabolic sub-volume also resulted in boosting the hypoxic volume, although
to a lower dose, but not vice versa.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 281–286
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).The prognosis of patients with advanced stage non-small cell
lung cancer (NSCLC) remains poor despite the use of new radiation
techniques and addition of chemotherapy to radiotherapy [1]. Poor
overall survival of patients treated with chemoradiotherapy is,
besides distant metastases, negatively related to insufﬁcient local
tumour control. Increasing the dose to the tumour may improve
local control, but escalating the dose to the whole tumour is cur-
rently limited by normal tissue toxicity [2,3].
Instead of escalating the dose to the whole tumour, a more
sophisticated approach may selectively increase dose to treatment
resistant areas while maintaining the dose to other parts of the tar-
get volume: a concept called dose painting [4]. Tumours are known
to be heterogeneous and biological properties, such as hypoxia, celldensity, proliferation and vascularisation, vary throughout the
tumour. As a consequence, some parts of the tumour are more
treatment resistant than others [5,6]. This biological knowledge
is integrated in dose painting to create highly personalised treat-
ment plans. Dose can be prescribed to individual voxels (i.e. dose
painting by numbers [7]) or to tumour sub-volumes (i.e. dose
painting by contours [4]). Dose painting by contours has the
advantage that clinical treatment planning software can be used
and a robust plan can be created using margins to account for
uncertainties. This latter approach is currently being tested in
several clinical trials [8,9].
Dose painting requires an imaging biomarker to determine
sub-volumes that are more treatment resistant and should there-
fore receive a higher dose. By selecting the appropriate positron
emission tomography (PET) tracer, biological processes like
hypoxia and glycolytic metabolism can be imaged. Hypoxia is a
tumour characteristic that is known to be correlated with tumour
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tracer 3-[18F]ﬂuoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1
H-1,2,3-triazol-1-yl)propan-1-ol (HX4) is an example of a PET tra-
cer whose ability to assess tumour hypoxia non-invasively has
been validated [12–15]. Another biological process that can be
assessed is tumour glucose metabolism, which is imaged with
the commonly used tracer 18F-ﬂuorodeoxyglucose (FDG). For
FDG-PET, it has been shown that volumes of local relapse are cor-
related with high uptake regions on pre-treatment images and are
stable over time [16–19].
The question of which imaging surrogate should be used for
dose painting is still under debate, but several surrogates have
been and are being used in clinical trials [8,9,20,21]. FDG is com-
monly used and widely available; its high pre-treatment uptake
is related to local relapses. However, spatial correlation between
uptake and local recurrences is not perfect. Aerts et al. [18] found
that 30% of relapses were outside the high FDG region. On the other
hand, hypoxia is known to be an important factor in chemotherapy
and radiotherapy resistance. Although hypoxia imaging has only
been used in clinical trials so far, these tracers are receiving more
attention for dose painting purposes.
Zegers et al. [22] compared metabolic and hypoxic uptake pat-
terns and found a good correlation between high uptake volumes
of both tracers for most patients. For frequently used thresholds,
the hypoxic volumes were generally smaller than the high meta-
bolic uptake volumes. Consequently, creating a boost plan based
on hypoxia imaging may reduce the boost volume and increase
dose-escalation levels even further. However, since margins have
to be added in dose painting by contours to account for treatment
delivery uncertainties, smaller high uptake sub-volumes on PET do
not automatically result in smaller planning boost volumes.
Furthermore, Zegers et al. [22] described a partial mismatch
between hypoxic and metabolic volumes in some patients. For
those patients, it is a priori unknown what effect the selected boost
volume with appropriate margins will have on the dose distribu-
tions of different dose painting plans.
Therefore, we compared different dose-escalation strategies to
determine the inﬂuence of the used imaging biomarker on
achieved tumour dose levels. For each patient, we created an iso-
toxic dose-painting plan boosting the FDG high uptake volume
and a plan boosting the hypoxic volume. For comparison, a plan
with a boost to the whole tumour was created. We evaluated the
feasibility of these treatment plans together with dosimetrically
achieved parameters for organs-at-risk dose and target volume.
Furthermore, we evaluated the accuracy of a particular imaging
surrogate for dose boosting on the coverage of the other biological
sub-volumes.Materials and methods
Patients
NSCLC patients who were inoperable or had irresectable disease
(cT2–T4, stage IB-III) were included in an ongoing phase II ran-
domised clinical trial (NCT01024829). To be eligible, the primary
tumour had to have a minimum diameter of 4 cm and maximum
standardised uptake value (SUVmax)P 5 on pre-treatment
FDG-PET [8]. The study was approved by the Medical Ethics
Review Committee and all patients gave written informed consent.
A dummy treatment plan was generated and a minimal dose of
72 Gy in 24 fractions (i.e. 3 Gy/fraction) to the planning target of
the primary tumour (PTVprim) ought to be feasible before randomi-
sation was performed. We selected patients with hypoxic
sub-volumes as detected on HX4-PET for this study.Image acquisition
Patients were scheduled for FDG-PET/CT and hypoxia
HX4-PET/CT scans on different days, within the same week before
radiotherapy. A pre-treatment respiratory gated 4D FDG-PET/CT
was acquired using a Siemens Biograph 40 PET/CT scanner
(Siemens Healthcare, Erlangen, Germany), according to the
NEDPAS protocol [23]. HX4-PET/CT acquisition was performed four
hours after injection of the hypoxia tracer on a Philips Gemini TF
64 scanner (Philips Healthcare, Best, the Netherlands) [13].
Patients were scanned in treatment position on a ﬂat table top
using the same ﬁxation devices.Boost volumes
Gross tumour volumes of the primary tumour (GTVprim) and
involved lymph nodes (GTVln) were delineated on the
mid-ventilation phase of the 4D FDG-PET/CT scan by an experi-
enced radiation oncologist. A 5-mm margin was added to the
GTVprim to include microscopic disease extension and create the
clinical target volume (CTVprim). An individualised margin, depend-
ing on the movement of the tumour on the 4D planning CT, was
added to the CTVprim to create the planning target volume
(PTVprim) [24]. For the lymph nodes, we used a 5-mm CTV and
5-mm PTV margin irrespective of the motion of the nodes.
The PTVprim was used as uniform boost planning target for plan
A; additional structures were created to boost the metabolic and
hypoxic sub-volumes. Boosting the metabolic target (GTVFDG)
was based on FDG-PET/CT and deﬁned as the region within
GTVprim with an SUV above 50% of SUVmax (Plan B). Since the
FDG-PET/CT scan was used as planning CT, no additional registra-
tion of the PET to the CT had to be performed. Boosting the hypoxic
volumes (GTVHX4) was based on HX4-PET/CT (plan C). The
HX4-PET/CT scan was registered rigidly to the planning
FDG-PET/CT scan using the treatment planning system (Eclipse
version 11.0, Varian Medical Systems, Palo Alto, CA). We applied
a bony anatomy match, followed by a soft tissue match with the
primary tumour as region of interest. Background was deﬁned as
mean uptake in the aortic arch. Voxels with a
tumour-to-background ratio (TBR) > 1.4 within the GTVprim were
classiﬁed as GTVHX4. The TBR >1.4 cut-off value was chosen based
on published research [12,25–27]. For GTVFDG and GTVHX4, we used
the same individualised GTV-PTV margins to create PTVFDG and
PTVHX4 [8].Organs-at-risk
Organs-at-risk (OAR) were delineated on the planning
FDG-PET/CT. Dose constraints were chosen according to the ongo-
ing clinical trial protocol [8,28]: lungs Dmean < 20 Gy (corrected to
EQD2); spinal cord D0.1 < 51 Gy (EQD2 < 52 Gy); oesophagus
V36 < 80% [29]; brachial plexus D0.1 < 66 Gy (EQD2 < 66 Gy); whole
heart Dmean < 46 Gy (EQD2 Dmean < 46 Gy); planning organ-at-risk
volume mediastinal structures (OAR + 5-mm margin) D0.1 < 76 Gy
(EQD2 < 94 Gy), where Dmean is the mean dose, D0.1 the dose deliv-
ered to 0.1% of the OAR, V36 the volume receiving 36 Gy and EQD2
the equivalent 2 Gy dose. For the biological dose calculation, we
used an a/b value of 3 Gy for the lungs, heart and mediastinal
structures, 2 Gy for the spinal cord and 10 Gy for the oesophagus.Treatment planning
Experienced radiation technicians created three volumetric
modulated arc therapy plans (VMAT; typically two half arcs for lat-
eral tumours and two full arcs for medial tumours) for each patient
using RapidArc (Eclipse version 11.0). Plans were created using a
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lated with a type B dose calculation algorithm (AcurosXB-10.0).
The prescribed dose was escalated until one or more of the OAR
constraints was reached, or when a maximum dose of 129.6 Gy
in 24 fractions in the PTVboost volume (PTVprim for plan A; PTVFDG
for plan B; PTVHX4 for plan C) was achieved. An isotoxic planning
strategy was applied to ensure equal lung toxicity. The target max-
imum mean lung dose difference between plans was 0.5 Gy. Plans
with a higher mean lung dose were downscaled and reoptimised.
This normalisation strategy has been shown to lead to similar
mean doses in the PTVprim [8].
The PTVboost was planned to have 99% of the volume covered by
90–115% of the prescribed dose. If there was overlap of less than
15% between PTVboost and OAR, a partial underdosage was
accepted: 85% of PTVboost was required to receive at least 90% of
the prescribed dose where the dose in the overlap volume was
escalated to 90% of the allowed OAR dose constraint. If this overlap
was more than 15%, no underdosing was accepted and 90% of the
prescribed dose should cover 99% of the target, equal to the
non-overlapping scenario. Lymph nodes were planned to receive
90–115% of 66 Gy. If PTVln overlapped with PTVprim, the PTVprim
was prioritised. Created treatment plans are available online at
https://www.cancerdata.org/10.1016/j.radonc.2015.07.013.Analysis of the plans
We calculated dose distributions and generated dose-volume
histograms for the three treatment strategies. We compared pre-
scribed and mean doses in the PTVprim between plans and calcu-
lated appropriate dose metrics for the OAR. We used a Wilcoxon
signed rank test in SPSS (IBM Corp., Version 22.0, Armonk, NY) to
compare prescribed doses and OAR doses between plan A, B and
C. The signiﬁcance level was adjusted for multiple comparisons
(Bonferroni correction): a p-value < 0.017 was assumed to be sta-
tistical signiﬁcant. Finally, we calculated the overlap between
PTVFDG and PTVHX4 to evaluate how boosting one of the two
sub-volumes affected the other sub-volume.Results
Between September 2011 and August 2014, 35 NSCLC patients
were included in the PET-boost clinical trial at our institute. 14
patients were not eligible because they did not receive a
HX4-PET/CT which was part of the translational research of the
trial and not mandatory for inclusion in the study, 8 patients did
not have a hypoxic tumour and in 3 patients dose-escalation up
to more than 72 Gy was not feasible. In total, 10 patients wereTable 1
Patient and tumour characteristics. Volumes of boost planning target for plan A (PTVprim),
Patient Gender Age (years) cTNM Stage Pathology
1 M 64 T4N2M0 IIIb Squamous cell carcinoma
2 F 65 T2N2M0 IIIa Adenocarcinoma
3 M 77 T3N2M0 IIIa Large cell carcinoma
4 M 82 T3N0M0 IIb Adenocarcinoma
5 M 66 T2N3M0 IIIb Unknown
6 M 71 T2N3M0 IIIb Adenocarcinoma
7 M 60 T4N1M0 IIIb Adenocarcinoma
8 M 65 T3N2M0 IIIa Squamous cell carcinoma
9 F 46 T3N2M0 IIIa Adenocarcinoma
10 M 66 T3N2M0 IIIa Adenocarcinoma
Mean 66 ± 10
Abbreviations: PTVprim = planning target volume of the primary tumour; PTVFDG = plann
volume.selected for this study. Patient and tumour characteristics are
listed in Table 1.
The mean GTVprim was 199 cm3 (range 32–853), mean GTVFDG
48 cm3 (range 15–85) and mean GTVHX4 30 cm3 (range 5–58);
see Supplementary Table 1. The respective mean planning target
volumes were 507 cm3 (range 149–1749), 173 cm3 (range 53–
484) and 114 cm3 (range 32–273). Table 1 presents the boost
volumes and overlap between those volumes. The volume encom-
passing both PTVFDG and PTVHX4 overlapped for 61% with PTVFDG
and for 87% with PTVHX4. As shown in Table 1, PTVHX4 was smaller
than PTVFDG for nine of the ten patients; PTVHX4 was almost com-
pletely within PTVFDG for eight patients. Patient 3 is an example of
such a patient: Fig. 1 shows both PET scans and the delineated
planning target volumes. Patient 7 (also shown in Fig. 1) is the only
patient with a spatial mismatch between FDG and HX4 high uptake
volumes.
It was feasible to generate plans with a boost to PTVprim, PTVFDG
and PTVHX4 for all patients. The dose distributions of two patients,
patient 3 and 7, are shown in Fig. 1. The corresponding dose–
volume histograms are displayed in Fig. 2. For both patients, the
histograms show that boosting the FDG volume also resulted in a
boost to almost the entire hypoxic volume, while boosting hypoxia
only increased the dose in part of the FDG high uptake volume.
For nine patients the highest dose was prescribed for plan C (see
Supplementary Fig. 1); the tenth patient had a larger PTVHX4 than
PTVFDG. The average prescribed doses to the boost volume were
87.1 ± 10.1 Gy (plan A), 107.3 ± 20.6 Gy (plan B) and
117.6 ± 15.2 Gy (plan C). The prescribed doses for plans B
(p = 0.005) and C (p = 0.005) were statistically signiﬁcantly higher
than for plan A. Prescribed doses and boost volumes per patient
are listed in Table 2. Comparing prescribed doses with respect to
boost volumes, Fig. 3, shows that it is generally more difﬁcult to
prescribe a high dose to large boost volumes.
The isotoxic planning approach resulted in no signiﬁcant differ-
ences in OAR doses (see Supplementary Table 2). Two examples of
OAR dose-volume histograms are shown in Fig. 2. Prescribed dose
was limited either by the mediastinal structures (seven patients),
or mean lung dose (three patients).
Discussion
We performed a dosimetric comparison of three clinically feasi-
ble dose-escalation plans for ten NSCLC patients: boosting FDG and
HX4 high uptake volumes was compared with boosting the entire
tumour. The size of the boost volume appears to be an important
factor for the height of the dose level that can be prescribed.
Hypoxia planning volumes were generally smaller than FDG boost
volumes, resulting in less overlap between target and surroundingplan B (PTVFDG) and plan C (PTVHX4), and the overlap between the planning volumes.
Planning boost volume (cm3) Overlap PTVFDG and PTVHX4
A B C (cm3) (% of PTVFDG) (% of PTVHX4)
558.4 188.4 129.5 124.1 65.9 95.8
148.6 61.6 40.7 38.7 62.8 95.2
651.0 246.4 139.7 122.0 49.5 87.3
259.4 80.2 32.3 31.7 39.5 98.2
300.0 136.2 131.2 118.8 87.3 90.6
173.3 53.2 36.8 35.8 67.3 97.2
1749.4 483.6 272.6 127.2 26.3 46.7
484.2 194.8 77.0 75.9 39.0 98.6
432.2 194.5 151.2 137.6 70.8 91.0
313.3 95.8 133.3 94.3 98.4 70.7
507 ± 466 173 ± 127 114 ± 73 91 ± 42 61 ± 22 87 ± 16
ing target volume of the high FDG sub-volume, PTVHX4 = PTV of the hypoxic sub-
Fig. 1. Example of pre-treatment FDG- and HX4-PET/CT scans. For patient 3 (top row) the GTVHX4 is smaller than the GTVFDG and the hypoxic volume is within the high FDG
volume, which is the case for most patients. Patient 7 (bottom row) is the only patient with a spatial mismatch between FDG and HX4 uptake. The dose distributions of plans
A, B and C are shown for the same patients. The red region is GTVprim, the magenta region GTVFDG and the cyan region GTVHX4. The line with corresponding colour represents
PTVprim, PTVFDG and PTVHX4, respectively. The isodose line of 90% of the prescribed dose to the lymph nodes is shown in yellow and 90% of the prescribed dose to the boost
region is shown in white. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Dose-volume histograms for the planning target volumes for the primary tumour (PTVprim), the high FDG volume (PTVFDG) and the hypoxic volume (PTVHX4).
Additionally, DVH for the organs at risk are plotted. Plan A is displayed as a solid line, plan B as a dashed line and plan C as a dotted line for the organs at risk. The top row,
patient 3, and bottom row, patient 7, are the same patients as depicted in Fig. 1.
284 Hypoxia and FDG PET based dose painting in NSCLCOAR. In two cases, underdosage of the boost volumes was allowed
in the hypoxia plan because overlap with the OAR was less than
the predeﬁned threshold (i.e. 15% of the volume), but it was not
tolerated for the other two plans. This facilitated further
dose-escalation in the hypoxia boost plan.
To our knowledge, this is the ﬁrst study showing the feasibility
of boosting hypoxia in NSCLC. This approach was already proven
feasible in head and neck cancer [30–33]. It is important to note
that not all patients were eligible for hypoxia boosting; 50% of
the patients had hypoxic tumours. We do not expect that this
approach is suitable for all patients; patient selection is essential
and treatment should be adapted for every patient. Patients with
non-hypoxic tumours have generally a better prognosis [34–38]and probably do not need an aggressive treatment as presented.
Based on pre-treatment hypoxia and FDG-PET/CT scans it can be
decided to boost hypoxic or FDG sub-volumes, or a combination.
For most patients the largest part of the hypoxic volume was
located inside the high FDG volume. As a consequence, boosting
FDG will also boost the hypoxia, but a boost to the hypoxic volume
will not escalate the dose in the entire FDG volume. For patients
without a hypoxia scan, FDG-PET imaging can be used as a surro-
gate for boosting hypoxia; however, less dose-escalation can be
achieved.
We used commonly applied thresholds to determine FDG and
HX4 high uptake sub-volumes, although these thresholds are arbi-
trarily deﬁned. The FDG threshold is already used in a clinical trial
Table 2
Prescribed dose and mean dose to the planning target volume in the primary tumour (PTVprim) for plan A (boost PTVprim), plan B (boost PTVFDG) and plan C (boost PTVHX4). Doses
were compared using a Wilcoxon signed rank test.
Patient Prescribed dose boost volumes (Gy) PTVprim Dmean (Gy)
A B C A B C
1 83.0 110.0 129.6 81.8 85.9 87.1
2 105.6 128.4 128.4 101.5 104.9 93.0
3 82.1 93.1 129.6 78.4 78.2 92.0
4 90.3 129.6 129.6 86.0 93.4 81.3
5 78.0 90.7 101.0 76.5 80.2 86.9
6 96.5 129.6 129.6 94.5 96.0 87.5
7 75.3 81.2 95.4 75.6 71.6 78.9
8 78.2 82.4 104.0 77.7 74.2 79.2
9 83.9 98.3 99.8 82.4 86.9 85.1
10 98.2 129.6 129.0 94.8 94.1 100.4
Mean 87 ± 10 107 ± 21 118 ± 15 85 ± 9 87 ± 11 87 ± 7
p-Value compared to plan A – 0.005 0.005 – 0.203 0.386
p-Value compared to plan B 0.005 – 0.028 0.203 – 0.878
p-Value compared to plan C 0.005 0.028 – 0.386 0.878 –
Abbreviations: PTVprim = planning target volume of the primary tumour; Dmean = mean dose.
Fig. 3. Prescribed dose to the boost region plotted as a function of the volume of the
boost volume. Analysis for plan A (boost PTVprim), plan B (boost PTVFDG) and plan C
(boost PTVHX4).
A.J.G. Even et al. / Radiotherapy and Oncology 116 (2015) 281–286 285[8], whereas the HX4 threshold is based on the literature [12,25–
27]. Zegers et al. [22] showed that the proportional overlap of
the tracers is rather stable for varying thresholds. That suggests
that the FDG plan will still boost the hypoxia volume with different
thresholds, but not vice versa. The different thresholds are likely to
have the greatest impact on the height of the prescribed dose
levels, as these are linked to boost volume (Fig. 3).
An important aspect that has to be considered in hypoxia dose
painting is stability of the target over time. Small studies testing
temporal stability of hypoxia in NSCLC have so far found inconclu-
sive results. Some studies have observed stable hypoxia [39,40],
whereas others have reported a decrease in hypoxia [26,41], or a
mix of stable and dynamic hypoxia [42]. Lin et al. [43] showed in
head and neck cancer that when there is a spatial shift, dose paint-
ing of the initial sub-volume still results in improved equivalent
uniform dose on a later scan. For pre-treatment FDG-PET/CT imag-
ing, it is known that most local relapses are within the FDG high
uptake region. However, it is still unknown whether
pre-treatment hypoxic regions also correlate with the locations
of local relapses. Because high correlations are observed between
FDG high uptake areas and hypoxic areas on pre-treatment scans,
we hypothesise that local recurrences will primarily occur in thesehypoxic regions. It is essential to conﬁrm this hypothesis before
applying hypoxia boosting in clinical practice. This will in the
future be assessed in the PET-boost clinical trial.
This study used a dose painting by contours approach.
Compared to dose painting by numbers, this approach is easier
to implement in clinical treatment planning software.
Furthermore, it includes a safety PTV margin to tackle small devi-
ations in target sub-volume deﬁnition.
Finally, there is still debate about the applicability and safety of
dose escalation in NSCLC. Although multiple clinical trials suggest
dose escalations could improve overall survival [44–46], a large
randomised phase III trial showed an unexpected lower survival
for the group that received a higher dose [47]. This unexpected
outcome may result from various causes including longer overall
treatment time, increased cardiac toxicity, or compromises in
deﬁning the PTV for the high dose group [48]. Alternatively, the
results may suggest that standard dose escalation is not the way
forward and more sophisticated dose redistribution techniques
are necessary to improve local survival.
In conclusion, selective boosting of sub-volumes based on FDG
or hypoxia is feasible and increases the prescribed dose compared
to whole tumour boosting, without increasing the dose to the
organs-at-risk.Conﬂict of interest statement
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